Trial Profile

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tomivosertib (Primary)
Indications Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Waldenstrom's macroglobulinaemia
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Effector Therapeutics

Most Recent Events

29 Nov 2018 Status changed from recruiting to discontinued.
08 Aug 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
08 Aug 2018 Planned primary completion date changed from 1 May 2019 to 1 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com